Mo1836 RESULTS AT 52 WEEKS OF INTRAVENOUS USTEKINUMAB MAINTENANCE TREATMENT IN PATIENTS WITH LOSS OF RESPONSE TO SUBCUTANEOUS DOSES: A MULTICENTER OBSERVATIONAL RETROSPECTIVE STUDY. | Publicación